| 2025 | Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence
| BREAST CANCER RESEARCH |
| 2025 | Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
| BMC CANCER |
| 2025 | Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (−) metastatic breast cancer patients in Korea (KCSG BR21-15)
| BREAST |
| 2025 | Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
| LANCET REGIONAL HEALTH-WESTERN PACIFIC |
| 2025 | Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer
| NPJ BREAST CANCER |
| 2025 | Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study
| CLINICAL BREAST CANCER |
| 2024 | Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
| BREAST CANCER RESEARCH |
| 2024 | Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
| NPJ BREAST CANCER |
| 2024 | De novo versus recurrent metastatic breast cancer affects the extent of brain metastases | JOURNAL OF NEURO-ONCOLOGY |
| 2024 | Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
| CANCER RESEARCH AND TREATMENT |
| 2024 | Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast Cancer
| JOURNAL OF BREAST CANCER |
| 2024 | Cytokine Release Syndrome in a Patient With Metastatic Triple-Negative Breast Cancer Treated With Hypofractionated Radiation Therapy, Who Had Previously Undergone Immunotherapy: A Case Report
| ADVANCES IN RADIATION ONCOLOGY |
| 2024 | Tumor-Infiltrating Lymphocyte Level Consistently Correlates with Lower Stiffness Measured by Shear-Wave Elastography: Subtype-Specific Analysis of Its Implication in Breast Cancer
| CANCERS |
| 2024 | Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
| YONSEI MEDICAL JOURNAL |
| 2024 | Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
| CANCERS |
| 2024 | Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer
| CANCERS |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
| CANCERS |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
| YONSEI MEDICAL JOURNAL |
| 2023 | Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy | RADIOLOGY |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
| INTESTINAL RESEARCH |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
| 2022 | SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
| CANCERS |
| 2022 | Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
| FRONTIERS IN IMMUNOLOGY |
| 2022 | Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
| NPJ BREAST CANCER |
| 2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
| ESMO OPEN |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2021 | Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer
| CANCERS |
| 2021 | PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
| BMC CANCER |
| 2020 | Clinical features and KRAS mutation in colorectal cancer with bone metastasis
| SCIENTIFIC REPORTS |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection | ANNALS OF SURGICAL ONCOLOGY |
| 2020 | Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study | TARGETED ONCOLOGY |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2019 | Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors
| Journal of Rheumatic Diseases |
| 2019 | Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma | Oncology |
| 2019 | A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
| CANCER RESEARCH AND TREATMENT |
| 2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| YONSEI MEDICAL JOURNAL |
| 2018 | Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma.
| CANCER RESEARCH AND TREATMENT |
| 2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
| 2017 | Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
| ONCOTARGET |
| 2017 | Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
| BMC CANCER |
| 2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| ONCOTARGET |
http://orcid.org/0000-0002-9044-8540
